Boston Scientific's Drive To Add To Core Strength Continues With BTG Buy
When Boston Scientific chief medical officer Ian Meredith spoke in mid-2018 of the group's appetite for core M&A, there was a sense that more strategic moves were likely before the year was out. The inference was right, and a busy year for Boston Scientific got much busier when it made a cash offer for UK interventional medicine specialist BTG PLC. The bid values the target company at $4.28 billion, and completion is expected by mid-2019.
You may also be interested in...
Manufacturing and supply chain resilience ensured that BTG Specialty Pharma met its sales target in the COVID-affected 2020. Its president, Anthony Higham, explained how this was possible while the company busily ̶ and quietly – sought new ownership, and all under the shadow of Brexit.
The sale of BTG Specialty Pharmaceuticals to two affiliates of European specialty firm SERB leaves Boston Scientific with BTG’s interventional oncology and vascular products.
The $800m sale of BTG Specialty Pharmaceuticals business to SERB leaves Boston Scientific with BTG’s successful interventional oncology and vascular products.